Recursion Announces Completion of Phase 1 Study for REC3964 for Clostridioides Difficile Infection

SALT LAKE CITY, Sept. 05, 2023 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has completed the Phase 1 study for REC-3964 in healthy volunteers. The study achieved its primary objectives of assessing the safety, tolerability and…Read More